A team led by Brazilian researcher Elis Eleutherio, professor at the Federal University of Rio de Janeiro, in partnership with
Continue reading »
Home »
AAN: Oral BTK inhibitor superior to placebo in multiple sclerosis
(HealthDay)—The selective Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib at a dose of 75 mg once daily is associated with fewer
Continue reading »
Multiple sclerosis: Small molecule could delay onset
Multiple sclerosis (MS) is a disabling disease that destroys the myelin sheath that protects nerve fibers, causing loss of signaling
Continue reading »